Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 25 points (-0.1%) at 16,936 as of Monday, July 28, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,030 issues advancing vs. 1,900 declining with 205 unchanged. The Health Services industry currently sits up 2.6% versus the S&P 500, which is down 0.2%. On the negative front, top decliners within the industry include AcelRx Pharmaceuticals ( ACRX), down 40.3%, Smith & Nephew ( SNN), down 2.1%, Fresenius Medical Care AG & Co. KGaA ( FMS), down 0.7% and Covidien ( COV), down 0.6%. Top gainers within the industry include Universal Health Services ( UHS), up 3.3%, Humana ( HUM), up 1.3%, Aetna ( AET), up 1.2% and WellPoint ( WLP), up 0.9%. TheStreet would like to highlight 3 stocks pushing the industry lower today: 3. Abbott Laboratories ( ABT) is one of the companies pushing the Health Services industry lower today. As of noon trading, Abbott Laboratories is down $0.31 (-0.7%) to $42.73 on light volume. Thus far, 1.5 million shares of Abbott Laboratories exchanged hands as compared to its average daily volume of 5.6 million shares. The stock has ranged in price between $42.62-$43.00 after having opened the day at $42.95 as compared to the previous trading day's close of $43.04. Abbott Laboratories manufactures and sells health care products worldwide. Abbott Laboratories has a market cap of $64.4 billion and is part of the health care sector. Shares are up 12.3% year-to-date as of the close of trading on Friday. Currently there are 10 analysts that rate Abbott Laboratories a buy, no analysts rate it a sell, and 6 rate it a hold. TheStreet Ratings rates Abbott Laboratories as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, expanding profit margins and increase in stock price during the past year. However, as a counter to these strengths, we find that net income has been generally deteriorating over time. Get the full Abbott Laboratories Ratings Report now. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.